ERBB2 (HF-158K1 Biosimilar) Recombinant Monoclonal Antibody

1. This abnormally sensitive electrochemical sensing performance resulting from anionic porphyrin for DNA sequences specific to HER2 gene will offer considerable promise for tumor diagnosis and treatment PMID: 30340409
2. Authors showed that mRNA and protein levels of COX2 and HER2 were upregulated in CRC compared with the adjacent tissues. COX2 protein levels and nuclear COX2 expression were correlated with a poor prognosis of CRC patients. COX2 expression was positively associated with HER2 expression. PMID: 29873317
3. In patients with HER2-positive advanced breast cancer who have been heavily pretreated with anti-HER2 agents and cytotoxic chemotherapy, trastuzumab emtansine (T-DM1) is well tolerated and provided a meaningful progression-free survival of 6 months and an overall survival that has not been reached. PMID: 29326401
4. The expression of C-Met and HER2 protein in lung adenocarcinoma is highly correlated, and whether it is synergistic in the targeted therapy of lung adenocarcinoma deserves further study. PMID: 29400000
5. Although ST6GalI overexpression increased HER2 sialylation, corresponding to decreased HER2 phosphorylation, high alpha2,6sialylation enhanced Akt and ERK phosphorylation levels compared to those in the vector cell line; ST6GalI knockdown had the opposite effects. Collectively, these results implicated a functional role of ST6GalI in promoting tumor cell progression and trastuzumab resistance. PMID: 30226606
6. Study demonstrate that the miR-495 exerts promotive effects on GC chemosensitivity via inactivation of the mTOR signaling pathway by suppressing ERBB2. The study provides reliable evidence supporting the use of miR-495 as a novel potential target in the chemotherapy of GC. PMID: 30147110
7. In early breast cancer, PIK3CA mutations seem to identify HER2+ patients who are less likely to reach pCR. The clinical implications of PIK3CA mutations tend to vary between exon 9 and exon 20. This mechanism should be explored in further studies. PMID: 29575819
8. HER2 and HER3 expression was detected in 22.2% and 86.1% of samples, respectively. The frequency of EGFR mutation was 45.7% and was not significantly different between stage 0 and IA1 (40.0% and 48.0%, respectively), suggesting that EGFR mutation does not correlate with cancer progression from stage 0 to IA1. PMID: 29473311
9. It has been demonstrated that the heterogeneity of HER2 expression accelerated the development of metastases which caused the poor survival of mice with heterogeneous HER2 expression (HER2-60). PMID: 30042341
10. Her-2/neu amplification increases with increasing grade of breast cancer. A high proportion of Her-2/neu gene amplified cases indicates aggressive disease in that area and need for FISH testing on large scale, which is the gold standard for equivocal cases on immunohistochemistry. PMID: 30060783
11. Data indicate that the major mechanism is the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. PMID: 28300085
12. Study showed the expression levels of Gli1 and HER2 were significantly higher in gastric cancer, and they are positively related. HER2 may regulate Gli1 by Akt-mTOR-p70S6K pathway. PMID: 29321573
13. The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations. PMID: 29567881
14. In the current settings, HER2/neu is not found to be a prognostic marker in head-and-neck cancers. PMID: 30004046
15. These results may be commented as HE4 expression rises in patients with HER2/neu amplification. PMID: 30004048
16. HER2 gene amplification in circulating tumor DNA predicts HER2-positive breast neoplasms resistance to trastuzumab emtansine. PMID: 29700710
17. Statistical analysis performed in this study did not reveal the significant relationship between HER2 overexpression on the tumor cells and microvessel density in the tumor stroma. PMID: 30334990
18. Data showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of proto-oncogene protein HER-2 (HER2) status is essential before any therapeutic decision. PMID: 30203148
19. HER2 gene amplification occurred during the early stages of gastric cancer and showed heterogeneity in several cases. HER2 gene amplification may be involved in tumor progression in early gastric cancer. PMID: 30120594
20. Activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer. PMID: 30094493
21. The results suggested a possible link between tRNALeu overexpression and RSK1/MSK2 activation and ErbB2/ErbB3 signaling, especially in breast cancer. PMID: 28816616
22. High HER2 expression is associated with metastasis in breast Cancer. PMID: 29187405
23. This study confirmed that biosimilar trastuzumab improves the overall response rate when combined with chemotherapy for HER2+ breast cancer PMID: 30082554
24. The Authors reveal a gender difference in the prognostic value of concomitant AIB1 and HER2 copy number gain (CNG) in glioma patients which were barely noticed before. These observations indicated that genetic alterations synergistic with essential respects of sex determination influence glioma biology and patients outcomes. PMID: 30153912
25. The survival rates in this study are equal to the documented global rates; nodal disease burden emerged as the most important prognostic factor. In addition, in EBCs, a lack of hormone receptor expression and in LABC, Her2neu overexpression appear to worsen the outcome. PMID: 30147088
26. Results showed that HER2 and FGFR2 are regulated by DDX6 at the post-transcriptional step in gastric cancer. PMID: 29987267
27. HER2 overexpression is associated with Gastric Cancer. PMID: 29938472
28. ERBB2 oncogene at 17q12 is susceptible to palindromic gene amplification in HER2-positive breast tumors. PMID: 28211519
29. Results show mutation in ERBB2-exon17 was associated with worse survival results in patients with pancreatic neoplasm. [review] PMID: 30227250
30. High HER2 expression and Gene Amplification is associated with Upper Tract Urothelial Carcinomas. PMID: 28755093
31. High HER2 expression is associated with invasion and lymph node metastasis in gastric cancer. PMID: 29970682
32. Basal HER2 phenotype showed poor DFS, but equivalent pCR rate after concurrent neo-adjuvant chemotherapy with trastuzumab. A different treatment approach to basal-HER2 type is needed even for cases that achieved adequate clinical response after neo-adjuvant chemotherapy. PMID: 29971625
33. In the largest series reported to date, patients with HER2-amplified m17 cancers treated with trastuzumab have outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive, supporting the critical role of HER2-directed therapy in this patient population. PMID: 28986743
34. The interplay of dual MET/HER2 overexpression in the AKT and ERK pathways for esophageal cancer is described. Therefore, combination therapy could be a novel strategy for EAC with amplification of both MET and HER2. PMID: 29223420
35. Study provides evidence that the hostile environment developed in spheroids has a key role in the acquisition of resistance to Trastuzumab and is associated with an increase in the number of breast cancer stem cells as well as a modulation in HER2 expression. PMID: 28722778
36. A major finding of our study is that one out of five (20%) patients with breast cancer BM had a receptor discrepancy between the primary tumor and the subsequent BM, with loss of hormone receptors (ER and/or PR) expression, and gain of HER2 overexpression as the most commonly observed changes PMID: 28975433
37. High HER2 expression is associated with Gastric Adenocarcinoma. PMID: 29802704
38. Absence of HER2 Expression of Circulating Tumor Cells is associated with Non-Metastatic Esophageal Cancer. PMID: 30275185
39. HER2 positivity was found in a minority of rectal cancer patients and was not significantly associated with clinicopathologic and molecular characteristics. PMID: 30056472
40. Study discovered a novel enhancer HER2 gene body enhancer (HGE) in the 3' gene body of HER2. The HGE activates promoters 1 and 2 in trans., and hence the TFAP2C-mediated transcriptional induction of HER2 expression in breast cancer samples. PMID: 29035388
41. ctDNA gene mutation profiles differed among HR/HER2 subtypes of metastatic breast cancer (MBC) patients. By identifying mutations associated with treatment resistance, we hope to improve therapy selection for MBC patients who received multiline treatment. PMID: 29807833
42. It was concluded that miR494 inhibited the cancer initiating cells phenotype and reversed resistance to lapatinib by inhibiting FGFR2 in HER2positive gastric cancer. PMID: 29786108
43. HER2 overexpression was evident in nearly 25% of the Malaysian patients with locally advanced or metastatic gastric cancer. The overexpression correlated significantly with male gender and diffuse-type tumors. PMID: 28124769
44. There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p=0.004), high Ki-67 expression (p<0.001) and development of visceral metastasis PMID: 29779938
45. The authors herein prove, for the first time, that the transcriptional repressor Blimp1 is a novel mediator of p130Cas/ErbB2-mediated invasiveness. Indeed, high Blimp1 expression levels are detected in invasive p130Cas/ErbB2 cells and correlate with metastatic status in human breast cancer patients. PMID: 28442738
46. ERBB2 amplification is driving resistance to erlotinib in lung adenocarcinoma. PMID: 28870636
47. Results showed that combining the results of IHC and FISH according to the HER2 testing algorithm is a useful method for accurately evaluating HER2-positive EMPD. PMID: 29744813
48. Because the concordance rates of HER2 IHC score 2/3+ cases were lower than that of HER2 IHC score 0/1+ cases, further studies for detailed analysis criteria for HER2 IHC score 2+ or 3+ are required. PMID: 28478639
49. HER2 interacts with Beclin 1 in breast cancer cells and inhibits autophagy. Mice with increased basal autophagy due to a genetically engineered mutation in Becn1 are protected from human HER2-driven mammary tumorigenesis. HER2-mediated inhibition of Beclin 1 and autophagy likely contributes to HER2-mediated tumorigenesis. PMID: 29610308
50. These findings suggest that early-stage morphological alterations of HER2-positive BC cells during cancer progression can occur in a physical and signalling-independent manner. PMID: 27599456

Show More

Hide All

HGNC: 3430

OMIM: 137800

KEGG: hsa:2064

STRING: 9606.ENSP00000269571

UniGene: Hs.446352